RESUMO
We present a case report of a 42-year-old woman with severe atopic dermatitis (AD) and history of alopecia areata (AA), which had been in remission for more than 5 years. She was treated with dupilumab for AD, and 4 months after initiating treatment, she developed a rapidly progressive reactivation of AA in an androgenic alopecia pattern. Alopecia resolved after a single intramuscular triamcinolone injection while the patient remained on dupilumab. This is the seventh report to date of dupilumab-associated alopecia but is the first case documenting reactivation of previous AA. Alopecia occurring after dupilumab initiation raises suspicion for a possible unrecognized adverse effect of dupilumab in AD patients.
Assuntos
Alopecia em Áreas/induzido quimicamente , Anticorpos Monoclonais Humanizados/efeitos adversos , Dermatite Atópica/tratamento farmacológico , Administração Tópica , Adulto , Alopecia em Áreas/tratamento farmacológico , Anticorpos Monoclonais Humanizados/uso terapêutico , Relação Dose-Resposta a Droga , Feminino , Humanos , Subunidade alfa de Receptor de Interleucina-4/antagonistas & inibidoresRESUMO
Systemic contact dermatitis (SCD) describes a hypersensitivity skin reaction following systemic re-exposure of an allergen in previously sensitized patients. Neomycin is an aminoglycoside antibiotic that, when taken orally, suppresses intestinal bacteria and is used in preoperative bowel surgery to reduce the risk of infection. While oral neomycin has been commonly associated with adverse reactions like nausea, vomiting, and Clostridium difficile-associated colitis, the poor intestinal absorption of oral neomycin makes systemic contact dermatitis an unusual adverse reaction. Herein we present a rare case of systemic contact dermatitis following oral neomycin administration.
